World Congress Tissue Engineering and Regenerative Medicine International

World Congress Tissue Engineering and Regenerative Medicine International Society Vienna, Austria September 5 -8, 2012 Industry Symposium Organized by TERMIS-AM and TERMIS-EU Industry Committees

TERMIS-AM Industry Committee • Established 2009 • Mission – Support commercialization in Tissue Engineering/Regenerative Medicine (TE/RM) • Goals – Define and address obstacles/hurdles to product commercialization – Promote collaborations to build a viable TE/RM industry • Members – – – Kiki B. Hellman, Ph. D; The Hellman Group. LLC; Chair Timothy A. Bertram, DMV, Ph. D; Tengion Peter C. Johnson, MD; Avery Dennison Mark Van Dyke, Ph. D; Wake Forest University Health Sciences Bill Tawil, Ph. D; Baxter Biosurgery 2

TERMIS-EU Industry Committee • Established 2011 • Mission – Motivate translation of academic research into commercial products, in Tissue Engineering/Regenerative Medicine (TE/RM) – Connect the scientific & clinical communities with TE/RM industries • Goals – Give answers to critical questions, paving the road of TE/RM commercial translation, by key stakeholders, from past experiences – Promote academia–industry meetings & partnerships for more effective commercial translation in TE/RM • Members – – – Yves Bayon, Ph. D; Covidien – Sofradim Production; Chair Simon Ellison, MBA; NHS Blood & Transplant John Barry, Ph. D; Baxter Innovations Paul Stroemer, Ph. D, Reneuron Chris Mason, Ph. D; University College of London Alain Vertes, Ph. D; London Business School Sloan Fellow 3

World Congress. TERMIS Industry Symposium Partnership, the key for successful translation of Regenerative Products Organized by TERMIS-AM and TERMIS-EU Industry Committees 4

World Congress Tissue Engineering and Regenerative Medicine International Society Vienna, Austria September 5 -8, 2012 Industry Symposium SESSION 1: “Commercialization of Regenerative Products: The Academe/Industry Partnership” Organized by TERMIS-AM and TERMIS-EU Industry Committees

Commercialization of Regenerative Products: The Academe/Industry Partnership Organizers: TERMIS-AM & TERMIS-EU Industry Committees Main Goals: • to learn from past academia-industry collaborative experiences in TE/RM commercial development • to enable academia and industry to understand how best to work together and identify individual collaborations that can rapidly move forward. 6

Commercialization of Regenerative Products: The Academe/Industry Partnership 9: 05 – 9: 20 Vienna/Austria - From a Strong Biomedical Tradition to a Future of Innovation and Patient Care Ehrlich H, Baxter Bioscience, Austria 9: 20 – 9: 40 Commercialization of regenerative medicine products: the academia-industry partnership Vertès A, London Business School, Sloan Fellowship, UK 9: 40 – 10: 00 Commercializing regenerative medicine therapeutics and sustaining a successful business Arshad A, Scientia Advisors, USA 10: 00 – 10: 15 Translating academic concepts to commercial medical products: A complex academic, industrial partnership Coury A, Consultant, USA 10: 15 – 10: 30 Successful translation of academic research using combinations of mesenchymal stromal cells with pharmaceutical agents for clinical applications in regenerative medicine Ghosh P, Mesoblast Ltd, Australia 7